Exciting Days at DCAT in New York!
Our team sends greetings and impressions from the Big Apple!
As we approach the final stretch of DCAT Week 2025 in New York, we reflect on an incredibly successful event so far! The Tiefenbacher Group team has had the privilege of engaging in insightful conversations, strengthening partnerships, and showcasing our latest innovations to make pharmaceuticals more affordable, more available, and better than ever before.
The dynamic atmosphere here in New York has been truly inspiring, and we are grateful for the many valuable exchanges with industry leaders and experts. As we head into the last day, we look forward to more meaningful discussions and new opportunities!
The DCAT Week in New York
For over 130 years, DCAT has provided a lifelong collegial community for its member companies and their representatives. It fosters relationships within its unique member company profile, encompassing the entire manufacturing value chain of the Bio/Pharmaceutical industry. DCAT offers objective, expert-driven educational programs and informational services, enabling its companies to gain insights into industry market trends, best practices, and the issues affecting the industry.
About Tiefenbacher Group – Pioneering Healthcare since 1963
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices and e-health-solutions. Our purpose is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.
For further information about our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products (including highly potent drugs) and e-health-solutions for global markets, please contact us by email at info@tiefenbacher.com or visit us on: www.tiefenbachergroup.com
Tiefenbacher Group, OnDosis and Star celebrate iF Design Award for OYSTA
We are proud to announce that OYSTA has been honored with the prestigious iF Design Award for its excellence in digital innovation and user-centric design.
This award is a testament to our shared vision and collaborative efforts of our partners—global life science company OnDosis AB and global technology consultancy Star—to redefine medication management for ADHD and beyond.
Improving ADHD care with digital innovation
OYSTA is more than a product—it’s a transformative solution designed to support medication adherence and enhance the care experience for young patients. By combining pharmaceutical expertise with e-health technology, OYSTA integrates two key components: the OYSTA Dosage Manager and the OYSTA Digital Service. Together, they enable intuitive, precise and flexible dosing, while providing connected care for patients, healthcare providers, teachers and carers.
The OYSTA Digital Service empowers effective ADHD management through tools for medication adherence, real-time data tracking and personalized insights. This breakthrough in personalized medication management improves the treatment experience for young patients and their circle of care.
A collaborative achievement setting a new standard in digital health
This transformative solution was made possible through the collaboration of OnDosis, who led its development, Tiefenbacher Group, which contributed its pharmaceutical expertise, and Star, which designed and built the OYSTA Digital Service—ensuring seamless integration between the physical dosing device and the digital ecosystem.
ADHD treatment is a complex, highly individualized process that requires precise dosage adjustments and continuous monitoring. OYSTA exemplifies an innovative healthcare solution that not only meets medical and technical standards but also prioritizes the needs of patients and healthcare providers. This milestone reflects our collective dedication to creating a patient-centric solution that sets a new standard in digital health—one that is both effective and accessible.
For more information about OYSTA, visit oysta-health.com.
Explore the work of our partners OnDosis at https://www.ondosis.com/ and Star at star.global
About Tiefenbacher Group – Pioneering Healthcare since 1963
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices and e-health solutions. The purpose is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.
For further information about TIEFENBACHER GROUP and our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products for global markets (including highly potent drugs) please contact us by email at info@tiefenbacher.com or visit us on: www.tiefenbachergroup.com
Lindus Health and Tiefenbacher Group Launching Clinical Trial
Lindus Health and Tiefenbacher Group are launching a clinical trial to advance ME/CFS research and treatment. At Tiefenbacher Group, we are committed to driving innovation in healthcare and addressing unmet medical needs.
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a serious and complex chronic condition affecting multiple body systems. Characterized by severe fatigue, post-exertional malaise (PEM), cognitive impairment, and other debilitating symptoms, ME/CFS significantly impacts the quality of life of those affected. Despite its prevalence of approximately 1%, there are currently no disease-targeted medications available, highlighting an urgent need for therapeutic advancements.
Research and Complexity
Understanding the complexity of ME/CFS requires a multi-faceted approach. Research suggests that potential triggers may include viral infections, immune system dysfunction, hormonal imbalances, and genetic predispositions. However, the exact pathophysiology remains unclear. This underscores the necessity of robust scientific exploration to identify novel treatment strategies that can alleviate symptoms and improve patient outcomes.
Research Efforts
Our commitment to pioneering healthcare is exemplified by our latest research efforts focused on ME/CFS. We aim to develop innovative treatment solutions that not only target symptoms but also address underlying disease mechanisms. By leveraging our expertise in pharmaceutical development and working alongside leading researchers, we strive to make a tangible difference in the lives of patients suffering from this debilitating condition.
Collaboration and Study Model
Collaboration is key to accelerating progress, which is why we are proud to partner with Lindus Health. Our ME/CFS study will leverage their decentralized clinical trial (DCT) model, allowing participants to move through screening, recruitment, and study procedures remotely from their homes. This approach enhances patient experience by providing greater flexibility and convenience. Recruitment will be conducted primarily through digital channels, while Lindus Health’s proprietary eClinical platform will facilitate participant pre-screening, data capture, and virtual study visits. Remote monitoring will be supported by wearable and digital health technologies, ensuring real-time and accurate data collection. Together, we are dedicated to pioneering a future where individuals with ME/CFS have access to effective treatments, ultimately enhancing their quality of life and restoring hope for a healthier tomorrow.
The Role of Lindus Health
Lindus Health is an innovative partner in the clinical research landscape, committed to accelerating the development of breakthrough therapies. Their expertise in running decentralized trials and leveraging digital health solutions plays a crucial role in ensuring the success of the ME/CFS study.
As we continue our mission to transform healthcare, we look forward to sharing the findings of this groundbreaking study. Upon completion, we will publish a detailed analysis of the results, reinforcing our commitment to transparency and scientific progress. Stay tuned for further updates as we pioneer the future of health together.
About Tiefenbacher Group – Pioneering Healthcare since 1963
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices and e-health solutions. The purpose is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.
For further information about TIEFENBACHER GROUP and our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products for global markets (including highly potent drugs) please contact us by email at info@tiefenbacher.com or visit us on: www.tiefenbachergroup.com
Tiefenbacher Pharmaceuticals Launch: Varenicline in UK
Tiefenbacher Pharmaceuticals successfully prepares the launch of Varenicline in the United Kingdom
We at Tiefenbacher Pharmaceuticals strongly believe that our high-quality medicines should be available and affordable for patients all around the world. That´s why we are thrilled to share that we have successfully prepared the launch of Varenicline in the UnitedKingdom!
WHO has added Varenicline to the list of essential medicines in 2021. This medicine is a cornerstone of the smoking cessation therapy helping patients to stop smoking in a short period of time (12 to 24 weeks).
Nevertheless, the originator brand Champix had to be withdrawn from the market in the same year due to the formation of nitrosamines in the manufacturing process. The European Medicines Agency has set clear quality standards for the product. Those need to be fulfilled before this important medicine could be made accessible again.
Tiefenbacher Pharmaceuticals brings the smoking cessation molecule Varenicline to patients in United Kingdom
In the last years, Tiefenbacher Group has successfully completed the formulation in its laboratories in Hyderabad, India. We are proud that we are the first who meet the European quality criteria. Together with our partners we are ready to be the first supplier that brings back Varenicline to smoking cessation patients in the United Kingdom.
Varenicline Citrate film coated tablets are marketed in the strengths 0,5 mg and 1 mg by our partners. This launch will not only improve the life of patients but also bring significant cost reduction for the healthcare systems. Untreated smoking addiction leads to a variety of follow-up diseases like premature atherosclerosis or coronary artery disease.
This launch reflects our ongoing commitment to providing patients with high-quality, affordable medicines. It is also a testament to the hard work and commitment of our team. We are excited about the positive impact this achievement will make.
In case of inquiries please reach out to licensing@tiefenbacher.com
TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes generic, value added, and innovative pharmaceuticals as well as medical devices and e-health-solutions worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets.
For more information about our finished dosage forms (FDF) including highly potent drugs and e-healthcare solutions, please contact us at info@tiefenbacher.com or visit us on www.tiefenbacher-pharmaceuticals.com
About Tiefenbacher Group – Pioneering Healthcare since 1963
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company. We are providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices and e-health solutions. The purpose is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.
For further information about TIEFENBACHER GROUP please contact us by email at info@tiefenbacher.com or visit us on: www.tiefenbachergroup.com
Tiefenbacher Group celebrating World Cancer Day
The 4th of February is the day to raise awareness of cancer worldwide.
Tiefenbacher Group joins the initiative led by the Union for International Cancer Control (UICC) to remind people that cancer has a global impact of around 20 million new cases each year and is a major public health challenge.
The new World Cancer Day campaign 2025-27 “United by Unique” places people at the center of care and will explore new ways of making a difference. In the fight against this disease, Tiefenbacher Group is committed to providing better and more affordable medicines to cancer patients around the world.
Tiefenbacher Group Pharmaceuticals
Thanks to our exceptional cancer pharmaceuticals, such as Abiraterone, Enzalutamide, Letrozole, Olaparib, Palbociclib, Regorafenib, Temozolomide, and Venetoclax, we have made significant progress towards our objective of providing more affordable medicines. Additionally, we can offer better therapies for patients through differentiated and innovative product solutions, including reducing the pill burden with improved posology, additional strengths, and suitable fixed-dose combinations. Moreover, we ensure better treatment compliance through personalized therapies by integrating medicines with advanced e-health solutions.
Our new state-of-the-art facilities in Hyderabad, India, will enable us to launch a sustainable pipeline of high potent cancer drugs which are planned to be developed and manufactured in-house.
About Tiefenbacher Group – Pioneering Healthcare since 1963
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices and e-health solutions. The purpose is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.
For further information about TIEFENBACHER GROUP and our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products for global markets (including highly potent drugs) please contact us by email at info@tiefenbacher.com or visit us on: www.tiefenbachergroup.com
Tiefenbacher Pharmaceuticals New Market Launch: Amifampridine
Tiefenbacher Pharmaceuticals Successfully Prepares the Launch of Amifampridine Across Europe
At Tiefenbacher Pharmaceuticals, we are deeply committed to making high-quality, life-changing medications affordable and accessible to patients worldwide, regardless of, nationality, or income. That’s why we are excited to share that we have successfully prepared the launch of Amifampridine Tablets 10mg. This is the first generic treatment for Lambert-Eaton Myasthenic Syndrome (LEMS), across Europe.
Amifampridine is an orphan drug and currently the only treatment available for LEMS patients. There is a critical need for 40,000 individuals worldwide aged 6 to 99 years suffering from this rare neuromuscular disorder. The product has been launched across key European markets and is marketed by our partners, ensuring broad access to patients in these regions.
A Fully In-House Supply Chain
This milestone reflects Tiefenbacher Group’s comprehensive in-house capabilities. Amifampridine was developed in our cutting-edge laboratories and manufactured in our most modern facilities in India and in Cyprus. The product has been packaged and dispatched by Tiefenbacher Group. Demonstrating our commitment to maintaining a fully internalized supply chain that underscores our dedication to quality and efficiency. This approach contributes to making the product more affordable.
Making Treatment Accessible and Affordable
LEMS is a rare condition with limited treatment options, and Amifampridine Tablets offer a much-needed, cost-effective alternative to the originator product. With a focus on better access and affordability, our product is significantly more affordable than the existing medications, ensuring that more patients can access the treatment they need without financial barriers.
Commitment to Rare Diseases
This launch marks an important step in Tiefenbacher Pharmaceuticals’ ongoing mission to address unmet medical needs. As the first generic Amifampridine on the market, our product provides new options to LEMS patients and highlights our dedication to improving patient care globally.
We are proud of our team and partners for their hard work, which made this achievement possible. This launch is a testament to the strength of our internal development and supply chain capabilities, we look forward to expanding access to Amifampridine in more markets in the near future.
In case of inquiries please reach out to licensing@tiefenbacher.com
TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes generic, value added, and innovative pharmaceuticals as well as medical devices and e-health-solutions worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets.
For more information about our finished dosage forms (FDF) including highly potent drugs and e-healthcare solutions, please contact us at info@tiefenbacher.com or visit us on www.tiefenbacher-pharmaceuticals.com
About Tiefenbacher Group – Pioneering Healthcare since 1963
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company. We are providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices and e-health solutions. The purpose is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.
For further information about TIEFENBACHER GROUP please contact us by email at info@tiefenbacher.com or visit us on: www.tiefenbachergroup.com
Tiefenbacher Group provides insights into practice
Insights into Practice: Tiefenbacher Group at the University of Kiel and Dusseldorf
Last week, Tiefenbacher Group had the fantastic opportunity to get in touch with pharmacy students at the University of Kiel and the University of Düsseldorf, to provide them insights into practice.
Together with our Managing Director Dr. Kristian Ruepp, Dr. Simon Bock from Market Access and Digital Strategy, and Dr. Patrick Indorf from Research & Development, two real-life cases were presented in Kiel. Along with Laura Sophie Steinecker from Research & Development and Dr. Kristian Ruepp, an additional “from API Distribution to Formulation Development” presentation occurred in Düsseldorf. Both events highlighting the challenges and innovations of the pharmaceutical industry. By sharing insights into our work, we aim to inspire the next generation of curious, healthcare-passionate talents. We want them to challenge the status quo and explore opportunities in the pharmaceutical industry.
Gratitude is extended to Prof. Dr. Regina Scherließ from Kiel University for the opportunity to participate in this lecture. Additionally, thanks to Prof. Dr. Jörg Breitkreutz from Düsseldorf University for allowing contributions to a lecture in the relatively new Master of Science in Industrial Pharmacy program.
A career in the pharmaceutical industry
We look forward to staying in touch with these talented students. Moreover, we are happy to play a part in helping them choose a career in the pharmaceutical industry – maybe they will shape a successful future with us at Tiefenbacher Group.
If you are also interested in a presentation by us for your university or if you are a student looking for an internship during your practical year, please contact our Human Relations Team around Marie-Theres Blumers, Chantal Gärtner and Johanna Boettcher.
About Tiefenbacher Group – Pioneering Healthcare since 1963
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices and e-health solutions. The purpose is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.
For further information about TIEFENBACHER GROUP and our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products for global markets (including highly potent drugs) please contact us by email at info@tiefenbacher.com or visit us on: www.tiefenbachergroup.com
Tiefenbacher Group celebrating International Day of Education
Every day is a new opportunity to learn something amazing!
On this International Day of Education, Tiefenbacher Group joins the global community in celebrating the transformative power of learning in building peaceful and sustainable societies.
At Tiefenbacher Group, we believe education is a fundamental right, crucial for personal and social growth. We are dedicated to promoting educational opportunities and fostering a curious future society. For this reason, we have built a school near our Tiefenbacher Laboratories in India, which is adorned with modern paintings depicting figures such as Albert Einstein and images of children playfully learning. These artworks aim to inspire and motivate students daily, emphasizing the importance of education and the joy of learning.
Let’s shape a brighter future together!
Undoubtedly, for Tiefenbacher Group, it is a rewarding experience to give back to the community. Our culture of caring is fundamental to achieving our goal of significantly improving the daily lives of people around the world. In the future, we will continue promoting education and health in various community engagement projects that align with our values and beliefs.
About Tiefenbacher Group – Pioneering Healthcare since 1963
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices and e-health solutions. The purpose is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.
For further information about TIEFENBACHER GROUP and our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products for global markets (including highly potent drugs) please contact us by email at info@tiefenbacher.com or visit us on: www.tiefenbachergroup.com
Tiefenbacher Group finalizing renovation
We are thrilled to announce the completion of the Tiefenbacher Group renovation of our office at the Port of Hamburg.
The finalization of the 4th floor marks a significant milestone, ensuring that our office environment is not only modern and innovative but also truly inspiring.
Our newly completed floor boasts three exceptionally spacious conference rooms with state-of-the-art technology, each featuring large windows that offer breathtaking views of the Elbe River. These rooms are designed to foster creativity and collaboration, providing the perfect setting for important meetings and brainstorming sessions.
In addition to the conference rooms, the floor includes two large open workspaces, a welcoming reception area, several smaller offices, and silence rooms that offer a quiet space for focused work. We have also dedicated a beautiful corridor to honor our founder, Alfred E. Tiefenbacher, with a portrait that serves as a reminder of our rich history and the visionary leadership that continues to drive us forward.
The Hamburg office a state-of-the-art workspace
This office modernization reflects our commitment to providing a state-of-the-art workspace that promotes the growth and well-being of our employees. The airy, transparent, and light-flooded interiors of our Hamburg office are intended to encourage innovation, partnership, and team spirit among our staff. These new branding elements integrated into the workspace emphasize our culture of professionalism, openness and the pioneering mentality that characterizes us.
As hybrid working and working from home have become the new normal for many, we are keen to keep our workspace at the cutting edge. We believe that our new premises on the banks of the Elbe offer a great working environment that supports the growth and well-being of our team.
Finally we would like to extend our heartfelt thanks to everyone who contributed to this project and made this transformation possible. We look forward to welcoming you to our new offices soon!
About Tiefenbacher Group – Pioneering Healthcare since 1963
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices and e-health-solutions. Our purpose is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.
For further information about our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products (including highly potent drugs) and e-health-solutions for global markets, please contact us by email at info@tiefenbacher.com or visit us on: www.tiefenbachergroup.com
Tiefenbacher Group wishes you a happy new year!
As 2024 draws to a close, the Tiefenbacher Group wishes you a Happy New Year and likes to share some of the year's highlights with you.
This year we celebrated many achievements: several international launches of prescription medicines, the preparation for Bilastine’s over-the-counter entry in Germany, the renovation of our Hamburg offices, and the construction of new labs and production buildings in Hyderabad, India.
2024, our sustainability efforts have been acknowledged with the EcoVadis Silver Medal on several occasions. Our social projects have not been neglected either: we started our strategic partnership with Pharmacists without Boarders, supported our school in India with several projects, and our employees have spent their social day in charitable institutions in Hamburg. Additionally our team in India spent their social day with collecting donations for the victims of the Rahat flood. And last but not least in December a significant part of our employees have donated a substantial amount for a good cause which got doubled by the management.
Furthermore, we have also been to numerous fairs and events to meet you in person. So we can tell you about our latest product portfolio and how we make pharmaceuticals more affordable, more available, and better than before!
Tiefenbacher Group is already looking very much forward to 2025. In this year, we want to continue to rock our markets by surprising patients with more affordable, more available and better-than-before medicines!
We hope the year 2025 will be as successful and full of unique moments as the past one and we are looking forward to meeting you again in person all over the world!
About Tiefenbacher Group – Pioneering Healthcare since 1963
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices. Our purpose is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.
For further information about TIEFENBACHER GROUP and our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products for global markets (including highly potent drugs) please contact us by email at info@tiefenbacher.com or visit us on: www.tiefenbachergroup.com